U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. About FDA
  3. Reports, Manuals, & Forms
  4. Reports
  5. Economic Impact Analyses of FDA Regulations
  6. Definition of the Term “Biological Product” Final Regulatory Impact Analysis
  1. Economic Impact Analyses of FDA Regulations

Definition of the Term “Biological Product” Final Regulatory Impact Analysis

The Food and Drug Administration is issuing a final rule to amend its regulation that defines "biological product" to incorporate changes made by the Biologics Price Competition and Innovation Act of 2009 (BPCI Act) and the Further Consolidated Appropriations Act, 2020 (FCA Act), and to provide its interpretation of the statutory term "protein." Under this final rule, the term protein means any alpha amino acid polymer with a specific, defined sequence that is greater than 40 amino acids in size. This final rule is intended to clarify the statutory framework under which such products are regulated.

Regulatory Impact Analysis

Definition of the Term “Biological Product” (PDF – 158KB)

Federal Register: 85 FR 10057, February 21, 2020

Docket: FDA-2018-N-2732

 

Back to Top